KemPharm Plans To License Out Commercial Rights For Pain, ADHD Candidates

 
• By Joseph Haas

KemPharm hopes a deep-pocketed company with neuroscience experience will want to market its prodrug of Ritalin for ADHD. For acute pain candidate Apadaz, the firm hopes to partner with a PBM that will price it to replace generics on formulary.

Profile of a human head with a colorful symbol of neurons in the brain

More from Strategy

More from Business